InvestSMART

Imricor Medical Systems Inc (ASX:IMR)

ALERT: Price-sensitive ASX Announcement for IMR
Current share price for IMR : $1.635 0.16 (10.85%)+
Announcement
Release
22 Oct 2025 9:42AM
Price at Release
$1.475
Full Release
download
Summary
Imricor Medical Systems Inc released its Q3 CY25 quarterly activities report, highlighting significant advancements in regulatory and commercial efforts. The company submitted 510(k) approval applications for the NorthStar and Vision-MR Diagnostic Catheter with the FDA and completed a Human Factors Study involving 20 hospitals. In Europe, NorthStar was commercially launched following CE Mark approval, and Imricor received regulatory approval to manufacture catheter shafts in-house. Financially, Imricor reported cash receipts of $124k, impacted by non-revenue generating clinical trials, and operating cash outflows of US$4.8m. The company maintained a cash balance of US$38.3 million and short-term investments of US$7.5 million. Imricor is focused on expanding clinical trials and driving the adoption of its MRI-compatible cardiac ablation products, anticipating strong market growth driven by the completion of VISABL-VT and VISABL-AFL trials.
Key Points
  • Submitted 510(k) approval for NorthStar and Vision-MR Diagnostic Catheter to FDA.
  • Completed Human Factors Study with 20 hospitals.
  • NorthStar launched commercially in Europe post-CE Mark approval.
  • In-house catheter shaft manufacturing approved for higher margin revenue.
  • Cash receipts of $124k, with operating cash outflows of US$4.8m.
  • Cash balance of US$38.3 million with short-term investments of US$7.5 million.
  • Focus on expanding clinical trials and market adoption of MRI-compatible products.
  • VISABL-VT and VISABL-AFL trials as key growth drivers.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.